Ge Healthcare As

Ge Healthcare Limited

Hammersmith Imanet Limited

Duncan George Wynn

Ian M Newington

Alan Cuthbertson

Harry John Wadsworth

Robert James Domett Nairne

Veronique Morisson-Iveson

Mikkel Jacob Thaning

Oskar Axelsson

Magne Solbakken

Erik Arstad

Julian Grigg

Anthony Eamon Storey

Matthias Eberhard Glaser

Sajinder Kaur Luthra

Frank Brady

Steven Michael Fairway

Imtiaz Ahmed Khan

Alexander Mark Gibson

Hanno Priebe

Marivi Mendizabal

Ian Andrew Wilson

Clare Louise Jones

Joanna Marie Passmore

Joseph Maduabuchi Arukwe

Nicolas Lasbistes

Amanda Ewan

Karina Martha Langseth-Manrique

Nicholas Toby Jeffery

Lars-Göran Wistrand

Alessandra Gaeta

Sally-Ann Ricketts

Julie Davis

Kirsty Heywood

Michael Schafers

Stefan Wagner

Hans-Jörg Breyholz

James Nairne

Gareth Humphries

Gareth Edwin Smith

Ian Martin Newington

Véronique Morisson-Iveson

Disclosed herein are novel procedures, systems and excipient solutions for in situ provision of a contrast media at a user defined concentrations. An automated procedure according to embodiments of the current invention provides increased user safety, flexibility and user friendliness.

Tailored dose of contrast agent

The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification ofF-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.

Radiolabelling method

Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described. 

Heterocyclic compounds as imaging probes of tau pathology

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds of the formula R&#x2014;Y&#x2014;X&#x2014;Z&#x2014;R where each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties, Y and Z are urea and urethane groups and X is a alkylene group which may be further substituted. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.

Contrast agents

Compounds of formula (I) R&#x2014;CO&#x2014;N(R)&#x2014;(CR)&#x2014;N(R)&#x2014;Rand salts or optical active isomers thereof, wherein each Rindependently are the same or different and denotes a hydrogen atom, a hydroxyl group, a Cto Cstraight of branched alkyl group or a Cto Cstraight of branched oxyalkyl group; Rdenotes a hydrogen atom or a Cto Cstraight of branched alkyl group; Rindependently are the same or different and denotes a acyl moiety; Rand Rindependently are the same or different and denote a triiodinated phenyl group, preferably a 2,4,6-triiodinated phenyl group further substituted by two groups Rin the 3 and 5 positions wherein each Rare the same or different and denote a hydrogen atom or a non-ionic hydrophilic moiety, provided that at least one Rgroup in the compound of formula (I) is a hydrophilic moiety; and n denotes a positive integer of 1 to 6. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.

The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

Diagnostic imaging agents with MMP inhibitory activity

The invention relates to novel processes for the purification of radiolabelled tracers, using a solid-support bound scavenger group. The general concept being illustrated by the scheme:

Purification methods

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing amide functions allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing hydroxyl groups allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to methods employing such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing urea or urethane functions allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.

Growing community of inventors

Amersham, United Kingdom

Duncan George Wynn